{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:22:17Z","timestamp":1790922137215,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.04.033","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:49:12Z","timestamp":1747669752000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term Oncological Outcomes for Patients with Non\u2013muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment"],"prefix":"10.1016","volume":"12","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Del","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Oberneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Rodr\u00edguez Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso Lafuente","family":"Puentedura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ca\u00f1o","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.04.033_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0015","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0025","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/BLC-160053","article-title":"Summary and recommendations from the National Cancer Institute\u2019s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.04.033_b0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0040","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-019-02956-6","article-title":"Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"145","author":"Kim","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0045","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0050","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high\u2013risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0055","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non\u2013muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M18-2782","article-title":"Balancing protection and free movement of personal data: the new European Union General Data Protection Regulation","volume":"170","author":"Bentzen","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.04.033_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2014.06.024","article-title":"Guidelines for reporting of statistics in European Urology","volume":"67","author":"Vickers","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.euo.2023.12.008","article-title":"Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer","volume":"7","author":"Li","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0075","doi-asserted-by":"crossref","first-page":"451.e1","DOI":"10.1016\/j.urolonc.2024.06.026","article-title":"Mitomycin C vs. bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center","volume":"42","author":"Scilipoti","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.04.033_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer\u2014current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euf.2025.04.033_b0090","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.04.033_b0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euf.2022.09.007","article-title":"long-term recurrence and progression patterns in a contemporary series of patients with carcinoma in situ of the bladder with or without associated Ta\/T1 disease treated with bacillus Calmette-Gu\u00e9rin: implications for risk-adapted follow-up","volume":"9","author":"Subiela","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.04.033_b0105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.4103\/jfmpc.jfmpc_1302_20","article-title":"A study of medication compliance in geriatric patients with chronic illness","volume":"10","author":"Punnapurath","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.euf.2025.04.033_b0110","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non\u2013muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.033_b0115","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0120","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with bacillus Calmette-Gu\u00e9rin instillations for bladder cancer: time to reconsider the evidence and open the quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.04.033_b0125","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.04.033_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.04.033_b0140","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Longoni M, de Angelis M, et al. Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int. In press. https:\/\/doi.org\/10.1111\/bju.16645.","DOI":"10.1111\/bju.16645"},{"key":"10.1016\/j.euf.2025.04.033_b0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/13696998.2023.2189860","article-title":"Evaluating the cost-utility of intravesical bacillus Calmette-Gu\u00e9rin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK","volume":"26","author":"Grabe-Heyne","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.euf.2025.04.033_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.033_b0155","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.euo.2023.09.014","article-title":"A territory-wide study investigating the dose and efficacy of different bacillus Calmette-Gu\u00e9rin strains in patients with intermediate- and high-risk non\u2013muscle-invasive bladder cancer","volume":"7","author":"Liu","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:58:50Z","timestamp":1770145130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925001117"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.033","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Oncological Outcomes for Patients with Non\u2013muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}